On/Go’s end to end population management solution seamlessly combines high-quality rapid testing with real time data and analytics, driving targeted, manageable interventions. With On/Go, we can help you plan, predict, and prevent the next outbreak so we can get one-step closer to a post-quarantine future
We call our solution Diagnostics as a Service (DaaS). Our platform automatically collects, stores and analyzes test results, providing relevant data and information for decision makers in real time.
Our data acts like NOOA for weather - helping us all see the bigger picture in anticipation and plan, prevent, predict and protect our communities.
Our platform seamlessly integrates with On/Go and On/Go One rapid tests, offering a real-time solution to avoid costly shutdowns through rapid, targeted interventions. To support the fight against COVID-19, our portal provides:
Our data driven digital diagnostics solution enables us to act proactively, so that we can build a new-age COVID infrastructure – grounded by data.
On/Go is a solution like no other. By connecting testing with real-time data to keep track of your family and their current status, you'll know you are ready to embark together on the next family vacation, take your child to his/her sporting events, or just be confident when you are visiting your loved ones.
The On/Go and On/Go One tests have not been FDA cleared or approved but have been authorized by FDA under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
The On/Go COVID-19 Antigen Self Test and the On/Go One COVID-19 Antigen Home Tests are lateral flow chromatographic immunoassays intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal swab specimens directly from individuals within 7 days of symptom onset or without symptoms or other epidemiological reasons to suspect COVID-19
